Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gene Therapy Via Intravenous Injection of Lentiviral Vector (Ivlv-ADA) for the Treatment of Adenosine Deaminase-severe Combined Immunodeficiency (ADA-SCID)

NCT03645460 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.

NCT NCT03645460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03645460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gene Therapy Via Intravenous Injection of Lentiviral Vector (Ivlv-ADA) for the Treatment of Adenosine Deaminase-severe Combined Immunodeficiency (ADA-SCID)
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 30, 2027
Completion date
December 31, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenosine deaminase severe combined immunodeficiency (ada-scid)